Unicycive Therapeutics (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, completed for its pivotal RENAZORB bioequivalence (BE) study. The Company expects to report top-line data from this pivotal study by year-end 2022.
Disclosure
Unicycive Therapeutics (UNCY) is a client of RedChip Companies, Inc. UNCY agreed to pay RedChip Companies, Inc., a $10,000 monthly cash fee, beginning in October 2022, for 4 months of RedChip investor awareness services.
